Innovations in Immunoglobulin A Nephropathy: Shaping the Future of Treatment

Faculty

Jonathan Barratt, PhD, FRCP
The Mayer Professor of Renal Medicine
Department of Cardiovascular Sciences
University of Leicester
Honorary Consultant Nephrologist
John Walls Renal Unit, University of Leicester NHS Trust
Leicester, UK

Statement of Need

Immunoglobulin A nephropathy (IgAN) is a progressive glomerular disease and a leading cause of chronic kidney disease (CKD), with up to 40% of patients advancing to kidney failure within two decades. Despite guideline-recommended management emphasizing supportive care and RAAS inhibition, many patients continue to experience persistent proteinuria and declining renal function. Clinical practice remains inconsistent, particularly regarding the use of assessment tools and initiation of immunosuppressive therapies. While updated risk scoring models, AI-driven risk stratification tools, and biomarker-guided assessments have emerged, awareness and utilization in routine care are limited. As new therapies enter practice, clinicians require practical education to incorporate evolving evidence into patient care. To meet this need, a virtual journal club series will deliver concise, case-based learning that translates recent clinical trial findings into actionable strategies. This format is designed to foster reflection, support informed decision-making, and help nephrologists and other HCPs optimize treatment pathways for patients living with IgAN.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Assess the limitations of traditional management approaches for IgAN
  • Evaluate the latest safety and efficacy data on new and emerging treatment approaches for IgAN

Financial Support

This program is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Target Audience

Nephrologists, physician associates (PAs), nurse practitioners (NPs), and other HCPs managing patients with IgAN

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 0.75

CME Outfitters, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 0.75

This application-based activity is approved for 0.75 contact hours (0.075 CEUs) of continuing pharmacy credit (JA0007185-0000-25-062-H01-P).

Nurses (ANCC) 0.75

This activity is designated for 0.75 contact hours.

California Residents: Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 0.75 Contact Hours.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Physician Assistants (AAPA): 0.75

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 07/30/2026. PAs should only claim credit commensurate with the extent of their participation.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Professor Barratt reports the following financial relationships:

Consultant: Alexion Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc.; argenx; Arrowhead Pharmaceuticals, Inc.; Astellas Pharma US, Inc.; BioCryst Pharmaceuticals, Inc.; Calliditas Therapeutics AB; Chinook Therapeutics, Inc.; Dimerix; Galapagos NV; Novartis; Omeros Corporation; Travere Therapeutics, Inc.; Vera Therapeutics; and Visterra, Inc,

Grants: Alexion Pharmaceuticals, Inc.; argenx; Calliditas Therapeutics AB; Chinook Therapeutics, Inc.; Galapagos NV; GSK; Novartis; Omeros Corporation; Travere Therapeutics, Inc.; and Visterra, Inc.

Research Support: Alexion Pharmaceuticals, Inc.; argenx; Calliditas Therapeutics AB; Chinook Therapeutics, Inc.; Galapagos NV; GSK; Novartis; Omeros Corporation; Travere Therapeutics, Inc.; and Visterra, Inc.

The following individuals have no financial relationships to disclose:

Thai Nguyen, MD, MHA (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Thomas Mitchell, MSW (Planning Committee)
Felicia Oyedepo, MD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

JC-034-073025-45

Innovations in Immunoglobulin A Nephropathy: Shaping the Future of Treatment
Event Date: 07/30/2025